跳至主要内容
临床试验/NCT00587444
NCT00587444已完成3 期

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 270 人开始时间: 2001年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Mayo Clinic
入组人数
270
试验地点
1
主要终点
measure blood loss

研究概览

简要总结

Study has been completed and is in the data analysis and manuscript writing phase of the project.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult male and non-pregnant female patients scheduled for elective cardiac surgery requiring CPB will be eligible for enrollment.

排除标准

  • Age less than 18 or greater than 90 years; emergency surgery
  • Circulatory arrest
  • Combined non-cardiac procedures such as carotid endarterectomy
  • Congenital heart repair
  • Off-CPB coronary artery bypass grafting (CABG)
  • Clotting disorder
  • Fibrinolytic agents (e.g. streptokinase), severe hepatic disease
  • Aprotinin use
  • Cooling < 28 degrees C during CPB
  • Dialysis dependent renal failure; and
  • Platelet receptor GP3a/2b antagonists medication received within 48 hours of surgery. Patients that are not receiving tranexamic acid (TA) intraoperatively will be excluded.

研究组 & 干预措施

1

Other

control standard dose heparin dose

干预措施: Heparin (Drug)

2

Active Comparator

high dose heparin dose

干预措施: HH or high heparin (Drug)

3

Active Comparator

hepcon guided therapy

干预措施: heparin concentration HC (Drug)

结局指标

主要结局

measure blood loss

时间窗: within 48 hours

次要结局

  • transfusion requirements(48 hours)

研究者

发起方
Mayo Clinic
申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Optimal Heparin Dosing Regimens for Cardiopulmonary... | 临床试验